Top 10 Companies in the Medical Bio-based Chemicals Market (2026): Market Leaders Powering Global Healthcare

Medical Bio-based Chemicals Market – View in Detailed Research Report

The medical bio‑based chemicals market is projected to grow at a robust CAGR of 7.5% from 2025 to 2034, reflecting a strong shift towards sustainable manufacturing across the pharmaceutical and diagnostics sectors. Key drivers include regulatory incentives for green chemistry, rising demand for eco‑friendly drug excipients, and expanding bioprocessing investments.

Medical bio‑based chemicals encompass a range of renewable, biologically‑derived compounds such as biobased polymers, bio‑derived acids, aldehydes, amines, and enzymes. These materials serve critical roles as excipients, solvents, active pharmaceutical ingredients, and components of advanced drug delivery systems, diagnostics, and tissue engineering scaffolds.

Top 10 Companies in the Medical Bio-based Chemicals Market

1️⃣ BASF SE

Headquarters: Ludwigshafen, Germany
Key Offering: Eco‑Health portfolio – bio‑derived pharmaceutical excipients, sterilisation agents, and specialty biochemicals.

BASF has leveraged its long‑standing chemical expertise to develop a large‑scale biorefinery that produces GMP‑grade bio‑based intermediates for drug manufacturing. The company’s focus on renewable feedstocks and digital process control has positioned it as a leader in sustainable pharma chemistry.

Sustainability & Growth Initiatives:

• Investment in biorefinery capacity expansion to 1.5 Mt of bio‑based intermediates by 2030.
• Partnerships with major pharma firms to co‑develop green excipients for oncology and biologics.
• Carbon‑neutral manufacturing target by 2040.

2️⃣ Evonik Industries

Headquarters: Essen, Germany
Key Offering: Amino‑acid derivatives, bio‑based polymers, and specialty biochemicals for drug delivery and diagnostics.

Evonik’s “Biosynthetics” division focuses on high‑purity bio‑derived ingredients that enhance the safety and efficacy of pharmaceutical products. Its advanced fermentation platforms enable rapid scale‑up of bio‑based excipients.

Sustainability & Growth Initiatives:

• Integration of circular bio‑economy principles across the supply chain.
• Collaboration with research institutions on enzyme‑catalyzed synthesis.
• Target of 30% renewable content in all product lines by 2035.

3️⃣ Lonza Group

Headquarters: Basel, Switzerland
Key Offering: GMP‑grade bio‑based monomers, polymers, and enzymes for drug delivery and cell therapy.

Lonza’s bioprocessing facilities provide customized bio‑based solutions for pharmaceutical manufacturers, including scalable production of biodegradable polymers for implantable devices.

Sustainability & Growth Initiatives:

• Expansion of bioreactor capacity to support personalized medicine workflows.
• Investment in green chemistry labs for next‑generation excipients.
• Commitment to 100% renewable energy for all production sites by 2035.

4️⃣ DSM

Headquarters: Heerlen, Netherlands
Key Offering: Bio‑derived esters, poly‑esters, and specialty biochemicals for drug delivery and diagnostics.

DSM’s “Bio‑Chem” portfolio supplies high‑purity bio‑based intermediates that meet stringent regulatory standards for pharmaceutical use.

Sustainability & Growth Initiatives:

• Scaling up renewable feedstock sourcing to reduce carbon footprint.
• Partnerships with pharma giants for co‑development of green excipients.
• Investment in biorefinery technology to enhance yield and purity.

5️⃣ Ashland Global Holdings

Headquarters: Newark, USA
Key Offering: Specialty polymers for wound care, drug delivery, and diagnostics.

Ashland focuses on high‑performance bio‑based polymers that offer superior mechanical and biocompatibility properties for medical applications.

Sustainability & Growth Initiatives:

• Development of biodegradable polymer coatings for medical devices.
• Collaboration with academic partners on polymer innovation.
• Reduction of lifecycle emissions by 25% by 2030.

6️⃣ Novamont S.p.A.

Headquarters: Sesto San Giovanni, Italy
Key Offering: Bio‑based monomers for biodegradable stent coatings and drug delivery systems.

Novamont’s “Novamont Bio‑Polymers” line delivers renewable polymers that degrade under physiological conditions, enabling next‑generation medical devices.

Sustainability & Growth Initiatives:

• Investment in biorefinery capacity for high‑purity monomers.
• Partnerships with medical device manufacturers for biodegradable coatings.
• Target to achieve carbon neutrality across operations by 2035.

7️⃣ Green Biologics

Headquarters: London, United Kingdom
Key Offering: Pharma‑grade biorefinery platform converting agricultural waste into high‑purity glycerol derivatives and bio‑based solvents.

Green Biologics supplies customized, small‑batch bio‑based chemicals for niche pharmaceutical applications, emphasizing quality and sustainability.

Sustainability & Growth Initiatives:

• Utilization of waste biomass to reduce environmental impact.
• Strategic alliances with pharma SMEs for tailored solutions.
• Goal of zero‑waste manufacturing by 2030.

8️⃣ Dow Inc.

Headquarters: Midland, USA
Key Offering: Bio‑based solvents, excipients, and specialty chemicals for pharmaceutical formulations.

Dow’s “Bio‑Chem” division focuses on scalable production of bio‑derived chemicals that meet strict regulatory standards for drug safety.

Sustainability & Growth Initiatives:

• Investment in renewable feedstock supply chains.
• Partnerships with global pharma for green chemistry solutions.
• Carbon‑intensity reduction target of 40% by 2035.

9️⃣ Croda International

Headquarters: Holten, Netherlands
Key Offering: Bio‑based polymers, surfactants, and specialty chemicals for drug delivery and diagnostics.

Croda’s “Bio‑Chem” platform delivers high‑purity bio‑based excipients that enhance drug stability and bioavailability.

Sustainability & Growth Initiatives:

• Investment in circular bio‑economy processes.
• Collaboration with pharma R&D labs on sustainable excipient development.
• Target to source 50% of raw materials from renewable sources by 2035.

🔟 Amyris Inc.

Headquarters: Newbury, USA
Key Offering: Engineered yeast platforms for production of bio‑based pharmaceuticals and specialty chemicals.

Amyris harnesses synthetic biology to produce high‑value bio‑based excipients and active ingredients at scale.

Sustainability & Growth Initiatives:

• Investment in genome‑edited microbial strains for higher yield.
• Partnerships with pharma for green drug development.
• Commitment to zero‑emission production facilities by 2035.

Download FREE Sample Report

Get Full Report